INIMMUNE CORP

• UNIVERSITY OF MONTANA

  UEI DAY7Z8ZD48Q3 · not in the directory yet

  $11M

  Subcontractor to this prime · 5 sub-awards · latest Dec 9, 2025

  • National Institutes of Health
  • “CONTINUATION OF THE WORK PERFORMED UNDER PG25-61441-03. THE ADJUVANT DISCOVERY CONTRACT WILL IDENTIFY, CHARACTERIZE, AND ADVANCE NOVEL SYNTHETIC CLR‐BASED ADJUVANTS FOR USE IN COMBINATION WITH BACTERIAL AND FUNGAL ANTIGENS TO INDUCE A SAFE AND DURABLE TH17 AND/OR TH17/TH1 IMMUNITY. INIMMUNE CORPORATION WILL WORK CLOSELY WITH THE TEAM FROM UM TO COMPLETE THE PRIMARY HTRF HIGH THROUGHPUT SCREEN OF COMPOUND LIBRARIES AND ASSIST WITH MEDICINAL CHEMISTRY SAR AND ANALYTICAL CHEMISTRY WITH LEAD SCAFFOLDS.”
  • “CONTINUATION OF THE WORK BEING PERFORMED UNDER PG21-61162-02 AND PG25-61218-02 TO IDENTIFY, CHARACTERIZE, AND ADVANCE NOVEL SYNTHETIC IL-1R-BASED ADJUVANTS FOR USE IN COMBINATION WITH AN INFLUENZA VACCINE TO INDUCE RAPID AND SUSTAINED BROADLY PROTECTIVE IMMUNITY TO SEASONAL AND/OR PANDEMIC INFLUENZA VIRUS. INIMMUNE WILL OVERSEE ANALYTICAL ASSAY DEVELOPMENT, PHYSIOCHEMICAL CHARACTERIZATION, STABILITY AND SCALE-UP SYNTHESIS OF LEAD IL-1R ADJUVANTS IDENTIFIED IN RESEARCH AREAS 1-3 OF OVERALL SCOPE.”
  • “CONTINUATION OF THE WORK PERFORMED UNDER PG25-61369-03 AND PG25-61419-02. THE INIMMUNE TEAM, WILL BE RESPONSIBLE FOR 1) SCALE-UP AND PROCESS DEVELOPMENT OF UM-1098 ON A 50 GRAM SCALE, 2) DEVELOPMENT AND QUALIFICATION OF ANALYTICAL ASSAYS NECESSARY FOR API AND FINAL PRODUCT RELEASE, 3) DEVELOPMENT OF PRODUCT RELEASE SPECIFICATIONS AND MBR, 4) PREPARATION OF PRE-CGMP UM-1098 FORMULATION LOTS ON SUFFICIENT SCALE TO CONDUCT ALL NON-CLINICAL IND ENABLING STUDIES, AND 5) OVERSIGHT OF NON-GLP TOXICOLOGY AND PK/ADME STUDIES.”
• THE UNIVERSITY OF CHICAGO

  UEI ZUE9HKT2CLC9

  $1M

  Subcontractor to this prime · 1 sub-award · latest Jan 27, 2026

  • National Institutes of Health
  • “INIMMUNE WILL ASSIST THE UNIVERSITY OF CHICAGO AS A SUBCONTRACTOR WITH THE OVERALL GOAL OF DEVELOPING A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE INNATE IMMUNE RESPONSE. THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF-􀄮􀀃 􀁄􀁑􀁇􀀃 􀀬􀀯-6 PRODUCTION. A PRIMARY VACCINES AGAINST MANY DISEASES BUT HAVE STRUGGLED WITH FORMULATION AND THE UNPREDICTABILITY OF SYSTEMIC INFLAMMATION AND TOXICITY. THE SPECIFIC ACTIVITIES INIMMUNE WILL PERFORM AS A SUBCONTRACTOR ARE OUTLINED BELOW: YEAR 1 ACTIVITY: THE SUBCONTRACTOR SHALL ASSIST WITH THE DEVELOPMENT OF A SERIES OF MOLECULES BASED ON A COMBINATION OF AN IMMUNE-MODULATOR (PME-􀀘􀀙􀀗􀀞􀀃􀀥􀁄􀁉􀁈􀁗􀁌􀁑􀁌􀁅􀀌􀀃􀁄􀁑􀁇􀀃􀁄􀀃􀀷􀀯􀀵􀀃􀀤􀁊􀁒􀁑􀁌􀁖􀁗􀀃􀀋􀀬􀀱􀀬- 4001) 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR SHALL PROVIDE CONSULTING SUPPORT FOR THE SYNTHESIS OF PME- 564 DERIVATIVES. 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR SHALL SYNTHESIZE A SMALL-SCALE LOT OF INI-4001. 􀁸 SUB-ACTIVITY: THE CONTRACTOR WILL PROVIDE CONSULTING IN THE DESIGN OF MOLECULES BASED ON INITIAL RESULTS FOR SYNTHESIS OF SECOND SET OF TEST COMPOUNDS. YEAR 2 ACTIVITY: THE SUBCONTRACTOR WILL PROVIDE FORMULATIONS FOR TESTING DERIVATIVES OF PME-564 (BAFETINIB) IN COMBINATION WITH INI-4001 FOR ACTIVITY AND SELECT TOP PERFORMERS FOR DEVELOPMENT AS VACCINE CANDIDATES. 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR WILL INITIATE LIPOSOME FORMULATION GENERATION AND TESTING. 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR WILL INITIATE OIL-IN-WATER EMULSION FORMULATION AND DERIVATIVE GENERATION AND TESTING. YEAR 3 ACTIVITY: THE SUBCONTRACTOR SHALL CONTINUE WITH OPTIMIZATION AND DOWN-SELECTION OF FORMULATIONS. 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR WILL TEST LEAD FORMULATIONS FOR COMPATIBILITY WITH WHOLE VIRAL PARTICLES, MRNA VACCINES AND HA PROTEINS. 􀁸 SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE THE ANALYT”
• DUKE UNIVERSITY

  UEI TP7EK8DZV6N5

  $613.6K

  Subcontractor to this prime · 1 sub-award · latest Jan 29, 2026

  • National Institutes of Health
  • “2.1 ACTIVITY (RA-2A): THE CONTRACTOR SHALL PROVIDE THE EQUIPMENT, FACILITIES, AND OTHER RESOURCES REQUIRED TO DEVELOP AND MANUFACTURE FORMULATIONS FOR THE THREE TEST ADJUVANTS TO SUPPORT STUDIES DESCRIBED IN THIS PROPOSAL. (INIMMUNE)€¢ TASK 2.1.1: SUPPLY INI-4001 AND INI-2001 IN AQUEOUS FORMULATION FOR IN VITRO ASSAYS (EVANS LAB, MONTH 3)€¢ TASK 2.1.2: SUPPLY INI-4001 AND INI-2001 IN OPTIMAL FORMULATION FOR IN VITRO AND IN VIVO STUDIES (EVANS LAB, CONTINUOUSLY)€¢ TASK 2.1.3: FORMULATION COMPATIBILITY TEST FOR CPG, INI-4001 AND INI-2004 (BURKHART LAB, MONTH 9) €¢ TASK 2.1.4: FORMULATION TRANSWELL ASSAY FOR CPG, INI-4001 AND INI-2004 (BURKHART LAB, MONTH 2) 2.2 ACTIVITY (RA-2B): THE CONTRACTOR SHALL PROVIDE THE EQUIPMENT, FACILITIES, AND OTHER RESOURCES REQUIRED TO COMPARE THE IMMUNOGENICITY OF VARIOUS ADJUVANT FORMULATIONS FOR SUBLINGUAL IMMUNIZATION. (INIMMUNE)€¢ TASK 2.2.1: IN VIVO IMMUNOGENICITY WITH THREE FORMULATIONS (EVANS LAB, MONTH 24) O ELISAS FOR SERUM, FECAL AND SALIVA ANTIBODY RESPONSES€¢ TASK 2.2.2: IN VIVO IMMUNOGENICITY DOSE RESPONSE WITH OPTIMAL FORMULATION FOR EACH TEST ADJUVANT. (EVANS LAB, MONTH 24) O ELISAS FOR SERUM, FECAL AND SALIVA ANTIBODY RESPONSES”
• OREGON HEALTH & SCIENCE UNIVERSITY

  UEI NPSNT86JKN51 · not in the directory yet

  $466.1K

  Subcontractor to this prime · 1 sub-award · latest Dec 11, 2023

  • National Institutes of Health
  • “DEVELOPMENT OF NOVEL STING PATHWAY AGONISTS AS VACCINE ADJUVANTS”

No reported sub-awards as a prime contractor.

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.